Menu
Contact Us
Subscribe
Menu

Vertex

Articles on this Topic

Other Topics

Recent Articles

Generic versions of a lifesaving cystic fibrosis treatment will save patients $360,000 a year – expanding access and prolonging lives

Kaitlin Mara -
Generic versions of a cystic fibrosis treatment will now be available at $6,375 per child, per year under a new scheme – offering hope...

WHO Members meet to finalise the Pathogen Access and Benefit Sharing Instrument

Ellen 't Hoen -
In May 2025, the WHO member states adopted the Pandemic Agreement, but they left the work to establish an instrument for Pathogen Access and...

FDA approval of injectable lenacapavir for Pre-Exposure Prophylaxis (PrEP) opens the road to ending HIV

Ellen 't Hoen -
On 18th June 2025, the US Food and Drug Administration (FDA) approved the use of long-acting antiretroviral medicine lenacapavir (LEN-LA), for the prevention of...

Transfer of technology and know-how for the production of pandemic-related health products in the WHO Pandemic Agreement: The proverbial half glass 

Ellen 't Hoen -
A version of this brief was published on 13 June '25 by the Graduate Institute as part of their 'Governing Pandemic Snapshot' series: https://www.governingpandemics.org/gp-snapshot During...
Load more

Medicines Law & Policy

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.

Never miss a post! Sign up for ML&P's newsletter.

This work is licensed under Creative Commons. You are free to share, with attribution and without changes, for non-commercial purposes.